336 related articles for article (PubMed ID: 32564612)
21. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
22. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
23. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
24. Next-generation peptide vaccines for advanced cancer.
Yamada A; Sasada T; Noguchi M; Itoh K
Cancer Sci; 2013 Jan; 104(1):15-21. PubMed ID: 23107418
[TBL] [Abstract][Full Text] [Related]
25. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
26. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
27. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.
Lim HX; Lim J; Jazayeri SD; Poppema S; Poh CL
Biomed J; 2021 Mar; 44(1):18-30. PubMed ID: 33727051
[TBL] [Abstract][Full Text] [Related]
28. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
[TBL] [Abstract][Full Text] [Related]
29. Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4
Melssen MM; Fisher CT; Slingluff CL; Melief CJM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36939214
[TBL] [Abstract][Full Text] [Related]
30. Peptide vaccines against cancer, infectious diseases, and conception.
Naz RK; Dabir P
Front Biosci; 2007 Jan; 12():1833-44. PubMed ID: 17127424
[TBL] [Abstract][Full Text] [Related]
31. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
32. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
[TBL] [Abstract][Full Text] [Related]
33. The progress of peptide vaccine clinical trials in gynecologic oncology.
Tang M; Cai JH; Diao HY; Guo WM; Yang X; Xing S
Hum Vaccin Immunother; 2022 Nov; 18(5):2062982. PubMed ID: 35687860
[TBL] [Abstract][Full Text] [Related]
34. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
36. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.
Miller MJ; Foy KC; Overholser JP; Nahta R; Kaumaya PT
Oncoimmunology; 2014 Nov; 3(11):e956012. PubMed ID: 25941588
[TBL] [Abstract][Full Text] [Related]
37. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
38. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
[TBL] [Abstract][Full Text] [Related]
39. Immunization with synthetic VEGF peptides in ovarian cancer.
Wang B; Kaumaya PT; Cohn DE
Gynecol Oncol; 2010 Dec; 119(3):564-70. PubMed ID: 20822802
[TBL] [Abstract][Full Text] [Related]
40. Prospect and progress of personalized peptide vaccinations for advanced cancers.
Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
